Metabolic Surgery Is Renoprotective in Patients With Obesity, CKD
By Elana Gotkine HealthDay Reporter
FRIDAY, Sept. 27, 2024 -- For patients with obesity, type 2 diabetes, and estimated glomerular filtration rate (eGFR) 20 to 60 mL/min/1.73 m2, metabolic surgery is associated with a lower risk for progression of kidney impairment compared with glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment, according to a study published in the September issue of the Annals of Surgery.
Ali Aminian, M.D., from the Cleveland Clinic, and colleagues examined the renoprotective effects of metabolic surgery in patients with established chronic kidney disease (CKD). Patients with obesity, type 2 diabetes, and eGFR 20 to 60 mL/min/1.73 m2 who underwent metabolic surgery were compared to nonsurgical patients who received GLP-1RA treatment. The analyses included 425 patients: 183 in the metabolic surgery group and 242 in the GLP-1RA group, with a median follow-up of 5.8 years.
The researchers found that the cumulative incidence of the primary end point of CKD progression at eight years was 21.7 and 45.1 percent in the surgical group and nonsurgical group, respectively, with an adjusted hazard ratio of 0.40. At eight years, the cumulative incidence of the secondary end point of incident kidney failure or all-cause mortality was 24.0 and 43.8 percent in the surgical and nonsurgical groups, respectively (adjusted hazard ratio, 0.56).
"Metabolic surgery should be considered as a therapeutic option for patients with CKD and obesity," the authors write.
Several authors disclosed ties to the pharmaceutical and medical technology industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
26.5 Percent of Adults With Diabetes Used GLP-1 RA Injectables in 2024
THURSDAY, Aug. 14, 2025 -- In 2024, 26.5 percent of adults with diagnosed diabetes used glucagon-like peptide 1 receptor agonist (GLP-1 RA) injectables, according to an August...
Lupus Low Disease Activity State Attainable in Lupus Nephritis
THURSDAY, Aug. 14, 2025 -- In lupus nephritis, attainment of complete renal response (CRR)/partial renal response (PRR) and lupus low disease activity state (LLDAS) is associated...
Dietary Patterns Linked to Chronic Kidney Disease Risk
THURSDAY, Aug. 14, 2025 -- Compared with other dietary indices, Dietary Approaches to Stop Hypertension (DASH) and the Dietary Inflammatory Index (DII) provide chronic kidney...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.